The ACT chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ACT chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ACT stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ACT Detailed Price Forecast - CNN Money||View ACT Detailed Summary - Google Finance|
|View ACT Detailed Summary - Yahoo! Finance||View ACT Stock Research & Analysis - Zacks.com|
|View ACT Trends & Analysis - Trade-Ideas||View ACT Major Holders - Barrons|
|View ACT Call Transcripts - NASDAQ||View ACT Breaking News & Analysis - Seeking Alpha|
|View ACT Annual Report - CompanySpotlight.com||View ACT OTC Short Report - OTCShortReport.com|
|View ACT Fundamentals - TradeKing||View ACT SEC Filings - Bar Chart|
|View Historical Prices for ACT - The WSJ||View Performance/Total Return for ACT - Morningstar|
|View the Analyst Estimates for ACT - MarketWatch||View the Earnings History for ACT - CNBC|
|View the ACT Earnings - StockMarketWatch||View ACT Buy or Sell Recommendations - MacroAxis|
|View the ACT Bullish Patterns - American Bulls||View ACT Short Pain Metrics - ShortPainBot.com|
|View ACT Stock Mentions - StockTwits||View ACT Stock Mentions - PennyStockTweets|
|View ACT Stock Mentions - Twitter||View ACT Investment Forum News - Investor Hub|
|View ACT Stock Mentions - Yahoo! Message Board||View ACT Stock Mentions - Seeking Alpha|
|View Insider Transactions for ACT - SECform4.com||View Insider Transactions for ACT - Insider Cow|
|View ACT Major Holdings Summary - CNBC||View Insider Disclosure for ACT - OTC Markets|
|View Insider Transactions for ACT - Yahoo! Finance||View Institutional Holdings for ACT - NASDAQ|
|View ACT Stock Insight & Charts - FinViz.com||View ACT Investment Charts - StockCharts.com|
|View ACT Stock Overview & Charts - BarChart||View ACT User Generated Charts - Trading View|
Sin Is In With New Vice ETF
Posted on Wednesday December 13, 2017
AdvisorShares, an exchange traded fund provider known for its actively managed investment options, has launched a new ETF that capitalizes on vice and also one among the first to include targeted exposure ...
AdvisorShares Delivers Alcohol, Cannabis & Tobacco Exposure with New Actively Managed ETF
Posted on Monday December 11, 2017
BETHESDA, Md., Dec. 11, 2017 /PRNewswire/ -- AdvisorShares, a leading sponsor of actively managed exchange-traded funds (ETFs), announced today that the AdvisorShares Vice ETF (Ticker: ACT) will begin trading on Tuesday, December 12, 2017. ACT becomes the first ETF – among both passively managed and actively managed strategies – that provides concentrated exposure to select companies associated with alcohol, cannabis and tobacco. ACT's portfolio management team carries extensive experience in the capital markets and a well-established expertise of investing in this area of the equity markets, which includes the founder and original portfolio manager of the Vice Fund mutual fund (VICEX).
Drugmaker Teva looks to sell Medis business to help cut debt
Posted on Wednesday August 09, 2017
Teva Pharmaceutical Industries , the world's largest generic drugmaker, said on Wednesday it was looking for a buyer for its Medis business as it sells assets to pare down its debt burden. Teva, which last week reported a drop in second-quarter results and cut its outlook and dividend, acquired Iceland-based Medis as part of its acquisition of Actavis last year. "Teva is looking at every opportunity to focus our business and streamline operations, processes and structure," Teva said in an emailed statement to Reuters.
UK Supreme Court rules in favor of Lilly's Alimta patents
Posted on Friday July 07, 2017
Eli Lilly and Co won a years-long patent dispute with Actavis on Friday after the UK Supreme Court ruled that the generic drugmaker's versions of Lilly's top-selling cancer drug Alimta directly infringe on certain Lilly patents in Britain, France, Italy and Spain. Teva Pharmaceutical Industries Ltd owns the generic versions of Alimta in question after buying Allergan Plc's generic business Actavis last August.